Business
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems
Innovating as a global leader in cryoablation technologies, with 29 patents issued and allowedCryogenic pump enables multiple and longer duration procedures
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Innovating as a global leader in cryoablation technologies, with 29 patents issued and allowedCryogenic pump enables multiple and longer duration procedures without the need to refill liquid nitrogen, potentially expanding clinical indicationsCAESAREA, Israel, Jan. 18, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced it has received a Notice of Allowance from the Japan Patent Office (the \"JPO\") for IceCure's patent application titled \"Cryogen Pump\". The patent will be in effect until 2041. A patent for this invention has been issued in the European Union and is pending in other major markets, including the U.S.\nIceCure's novel cryogenic pump is submersible in liquid nitrogen, works in a closed circuit, improves the cooling rate during a procedure, and is designed to be used for multiple procedures or longer duration procedures without the need to refill liquid nitrogen. Moreover, this pump enables temperature control of the cryoprobe, as well as the use of a wider range of cryoprobes and catheters.\n\"With this Notice of Allowance from the JPO, IceCure continues to build upon its leadership position in cryoablation procedures worldwide. We believe the cryogen pump will be instrumental in enabling practitioners to perform longer-term and multiple procedures more efficiently, as well as allowing for the expansion of cryoablation treatment to more clinical applications in the future,\" stated Eyal Shamir, IceCure's Chief Executive Officer. \"This additional IP in Japan supports our distribution agreement with Terumo for our cryoablation systems in Japan.\"\nAbout IceCure Medical Ltd. IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the FDA and approved in European with the CE Mark.\nForwa...